The interactive visualizations below include submitted WAC Increase data for Q1 and Q2 2021. These graphs display data that shows Median Cumulative WAC Percent Increase by WAC Price Category, Drug Source Type, or Both. The graphs allow you to filter through the data by quarter.
Note: Reported increases that do not meet the statutory requirements for reporting and prescription drugs that do not meet the definition for reporting under the applicable California Regulations and Section 321(g) of Title 21 of the United States Code were not included in the visualizations. In Q1 and Q2 2021 combined, 33 of 877 reports did not meet the statutory requirements.
Median Percent Increase – WAC Price Category
- The total number of WAC increases reported to HCAI decreased significantly between Q1 and Q2 2021: 800 reports in Q1 2021 and 44 reports in Q2 2021.
- In Q2 2021, all WAC price categories saw 3-year median WAC percent increases above 24%.
- In Q2 2021, the largest 3-year median WAC percent increase was made on prescription drug products with a WAC under $250 (53.3%), followed by drug products with a WAC over $10,000 (31.2%).
Median Cumulative WAC Percent Increase by WAC Price Category (Q2 2021)
Median Percent Increase – Drug Source Type
- Approximately 70% of reported WAC increases made in Q2 2021 were made on Single Source Drugs (31 reports out of 44 total reports).
- The 3-year median WAC increase on Single Source Drugs in Q2 2021 (26.7%) was the smallest across drug types in that quarter.
Median Cumulative WAC Percent Increase by Drug Source Type (Q2 2021)
Median Percent Increase – WAC Price Category & Drug Source Type
- In Q2 2021, Non-innovator Multiple Source Drugs with a WAC under $250 saw the largest 3-year median WAC percent increase (105.9%).
- In Q2 2021, the only reported WAC increases made on prescription drug products with a WAC greater than $10,000 were made on Single Source Drugs.
Median Cumulative WAC Percent Increase by WAC Price Category and Drug Source Type (Q2 2021)
Data and Resources#
Topic: Cost Transparency
Temporal Coverage: January to June 2021
Spatial/Geographic Coverage: Statewide
Citation: Department of Health Care Access and Information (HCAI), Prescription Drug Cost Transparency
- The 3-year median percent increase is based on submitted WAC increase data.
- The dataset is subject to reporting. The dataset includes only complete reports submitted by manufacturers for WAC increases that were made in Q1 and Q2 2021, not including reports that do not meet the specified minimum thresholds for reporting.
- Manufacturers can submit late reports; any Q2 2021 WAC increase reports submitted after December 3, 2021, are not included in the data.
- Manufacturers are required to provide the reason(s) for reported WAC increases unless the information is not in the public domain. Approximately 59% of Q1 2021 and 43% of Q2 2021 reports did not include any reason(s) for the reported WAC increases due to the information not already being in the public domain.